Arcus Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company whose common stock trades on the New York Stock Exchange under RCUS. Form 8-K reports include quarterly and annual results furnished with pipeline updates, clinical program disclosures, collaboration updates, executive changes and material agreements tied to the company’s financing and development activities.
Arcus filings also cover capital structure and governance matters, including a completed common stock offering, amendments to a loan and security agreement, annual proxy materials, board and executive compensation disclosures, equity incentive matters and stockholder meeting proposals. The filing record reflects risk and operating disclosures connected to drug development, clinical studies, regulatory pathways, collaborations and funding needs.
A Rule 144 notice for Arcus Biosciences (RCUS) indicates that stockholder Robert C. Goeltz II plans to sell 14,000 shares of common stock through E*TRADE Financial on the NYSE, with an aggregate market value of 306,600 and an approximate sale date of 12/16/2025.
The shares to be sold come from restricted stock that vested on 12/15/2025 from grants originally awarded on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025 as consideration for services rendered. The notice also reports 122,856,086 shares outstanding and discloses additional recent sales by the same seller of 5,000 shares for gross proceeds of 125,000 on 11/26/2025 and 5,000 shares for 100,000 on 10/28/2025, providing context for his recent trading activity.
Arcus Biosciences, Inc. had a shareholder file a notice to sell 22000 shares of common stock through E*TRADE on the NYSE, with an aggregate market value of 481800. Shares outstanding were 122856086; this is a baseline figure, not the amount being sold.
The shares to be sold were acquired on 12/15/2025 through vesting of restricted stock granted on 03/08/2022, 01/23/2023, 01/23/2024 and 01/23/2025 as payment for services rendered. The same seller previously disposed of 12500, 37792 and 50291 shares of common stock on 10/06/2025, 10/08/2025 and 11/07/2025, respectively, for gross proceeds of 181800.77, 568610.88 and 954066.32, and represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Arcus Biosciences, Inc. (RCUS) has a planned sale under Rule 144 for 22,000 shares of common stock through E*TRADE Financial Corporation, with an aggregate market value of 481,800. Shares outstanding were 122,856,086 as indicated in the notice; this is a baseline figure, not the planned sale amount, and the exchange named is NYSE. The approximate sale date is 12/16/2025.
The shares to be sold were acquired on 12/15/2025 through the vesting of restricted stock grants originally awarded on 3/8/2022 and 1/23 of 2023, 2024 and 2025 in exchange for services rendered. Over the prior three months, The Juan Carlos Jaen and Anita Galeana 2000 Trust reported several sales of Arcus common stock, including 82,997 shares on 12/04/2025 for gross proceeds of 2,096,504.22.
Arcus Biosciences, Inc. has a shareholder filing a notice under Rule 144 to sell up to 55,000 shares of common stock through broker E*TRADE Financial, with an aggregate market value of $1,204,500 and an approximate sale date of 12/16/2025 on the NYSE.
The notice states that the securities to be sold were acquired through vesting of restricted stock on 12/15/2025, granted on 3/8/2022, 1/23/2023, 1/23/2024, and 1/23/2025 as compensation for services rendered.
Arcus Biosciences reported that it is discontinuing its Phase 3 STAR-221 study after an interim analysis showed that the domvanalimab-based regimen did not improve overall survival compared with nivolumab plus chemotherapy in first-line advanced gastric and esophageal cancers. A related Phase 2 EDGE-Gastric study will also be stopped. An Independent Data Monitoring Committee recommended ending the trial for futility, although the safety profile of the domvanalimab combination was similar to the control arm with no new safety issues identified.
The company and its partner Gilead are working with investigators on next steps for patients and will further analyze the data. Arcus stated that, based on its existing cash, cash equivalents and marketable securities, it expects to fund planned operations until at least the second half of 2028. R&D efforts will shift toward casdatifan, a potential best-in-class HIF-2a inhibitor, and early inflammation and autoimmune programs, including an MRGPRX2 inhibitor expected to enter clinical testing in 2026.
Arcus Biosciences, Inc. reported an insider stock sale by its president. A Form 4 filing shows that on 12/04/2025, the executive sold 82,997 shares of Arcus common stock at a weighted average price of $24.7069 per share, in multiple trades within a price range of $24.35 to $25.15. After these transactions, the reporting person beneficially owned 954,063 shares indirectly through a trust and 367,220 shares directly. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on August 8, 2025, which is designed to allow pre-arranged trading independent of day-to-day market conditions.
Arcus Biosciences insider plans additional stock sale under Rule 144. The Juan Carlos Jaen and Anita Galeana 2000 Trust filed a notice to sell 82,997 shares of Class A common stock of Arcus Biosciences through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of approximately $2,096,504.22. The filing notes that 120,801,086 shares of this class were outstanding at the time of the notice.
The trust originally acquired these shares from the issuer in a private transaction on 05/08/2015. Over the prior three months, the trust reported multiple open-market sales of Arcus Class A common stock, including 19,019 shares on 10/28/2025 and 77,167 shares on 10/29/2025, along with several smaller transactions, for total disclosed gross proceeds in the millions of dollars. The signatory represents that they are not aware of any undisclosed material adverse information about Arcus Biosciences.
Arcus Biosciences Chief Accounting Officer reports option exercise and share sale. On 11/26/2025, the officer exercised a stock option to acquire 1,900 shares of Arcus Biosciences common stock at $13.33 per share and on the same date sold 1,900 shares at $26 per share under a Rule 10b5-1 trading plan. After these transactions, the officer directly beneficially owned 27,363 shares of common stock and 9,500 stock options with a $13.33 exercise price, which are scheduled to become exercisable in 48 equal monthly installments after January 1, 2025 and expire on January 22, 2035.
Arcus Biosciences (RCUS) Chief Financial Officer reports stock sale under pre-arranged plan. The CFO sold 5,000 shares of Arcus Biosciences common stock on 11/26/2025 at a price of $25 per share in an open market sale coded as an "S" transaction. After this sale, the reporting person beneficially owns 87,138 shares of Arcus Biosciences common stock in direct ownership. The filing states that the sale was made under a Rule 10b5-1 trading plan, which is a pre-established program intended to allow insiders to sell shares according to set instructions.
Arcus Biosciences, Inc. (RCUS) reported insider stock sales by its President, who is an officer of the company. On November 17, 2025, a trust associated with the reporting person sold 37,114 shares of common stock at a weighted average price of $20.2274, and a further 7,836 shares at a weighted average price of $20.713. On November 18, 2025, the trust sold an additional 5,050 shares at a weighted average price of $19.75. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, the reporting person beneficially owned 1,037,060 shares indirectly through a trust and 367,220 shares directly.